Fig. 7

Proportion of icatibant-treated HAE attacks (with complete data for time to treatment, time to resolution and attack duration) in UK patients and non-UK patients according to a time to treatment, b time to symptom resolution and c duration of attack. HAE hereditary angioedema, Time to treatment time between the start of the attack and the first icatibant injection, Time to resolution time between first injection of icatibant and complete resolution of symptoms, Attack duration time between start of attack and complete resolution of symptoms. ^aNon-UK countries are Austria, Brazil, Denmark, France, Germany, Greece, Israel, Italy, Spain and Sweden. ^bGeneralized linear model for repeated measures